PharmaShots | Incisive News in 3 Shots

Subscribe Now

Tecentriq

Roche Reports Updated OS Data of Tecentriq + Avastin in P-III IMbrave150 Study for Unresectable HCC

Roche Reports Updated OS Data of Tecentriq + Avastin in P-III IMbrave150 Study for Unresectable HCC

January 12, 2021

Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma

Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma

November 3, 2020

Chugai's Tecentriq (atezolizumab) and Avastin (bevacizumab) Receive MHLW's Approval as 1L Treatment for Unresectable Hepatocellular Carcinoma

Chugai's Tecentriq (atezolizumab) and Avastin (bevacizumab) Receive MHLW's Approval as 1L Treatment for Unresectable Hepatocellula...

September 28, 2020

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

September 21, 2020

Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020

Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020

September 17, 2020

Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Car...

August 19, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us